Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Postoperative Pain · Pain · PCRX

Pacira Ireland

Pacira Ireland Limited

Pacira Ireland patent portfolio — 57 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
Ranelagh, IE HQ
2007 Founded
7 Employees
Public company Type
PCRX · NYSE Ticker
Company details
Status
Public
HQ
Ranelagh, IE
Founded
2007
Employees
7
Programs
100
Drugs
32
Patents
57
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

Pacira Ireland patents

57 pharmaceutical patents indexed for Pacira Ireland. 0 expire within 24 months.

Pacira Ireland has 57 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

57 patents

Patent portfolio

Page 1 of 2

  1. US 12370142

    Manufacturing of bupivacaine multivesicular liposomes

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12364764

    Sustained release thermosetting gels comprising sodium channel blockers and the methods of making same

    Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12318483

    Manufacturing of bupivacaine multivesicular liposomes

    Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12296047

    Manufacturing of bupivacaine multivesicular liposomes

    Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12285435

    Multivesicular liposome formulations of dexamethasone

    Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12285419

    Bupivacaine multivesicular liposome formulations and uses thereof

    Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12280149

    Manufacturing of bupivacaine multivesicular liposomes

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12251472

    Manufacturing of bupivacaine multivesicular liposomes

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12251468

    Manufacturing of bupivacaine multivesicular liposomes

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12246092

    Manufacturing of bupivacaine multivesicular liposomes

    Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12226610

    Treatment of pain associated with total knee arthroplasty with sustained-release liposomal anesthetic compositions

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12178909

    Manufacturing of bupivacaine multivesicular liposomes

    Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12156940

    Manufacturing of bupivacaine multivesicular liposomes

    Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12151024

    Manufacturing of bupivacaine multivesicular liposomes

    Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12144890

    Manufacturing of bupivacaine multivesicular liposomes

    Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11931459

    Treatment of pain in pediatric patients by administration of sustained-release liposomal anesthetic compositions

    Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11925706

    Manufacturing of bupivacaine multivesicular liposomes

    Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11918565

    Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11918688

    Treatment of hip pain with sustained-release liposomal anesthetic compositions

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11819572

    Treatment of pain by administration of sustained-release liposomal anesthetic compositions

    Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11819573

    Treatment of hip pain with sustained-release liposomal anesthetic compositions

    Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11819574

    Manufacturing of bupivacaine multivesicular liposomes

    Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11819575

    Manufacturing of bupivacaine multivesicular liposomes

    Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11813357

    Treatment of hip pain with sustained-release liposomal anesthetic compositions

    Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11759459

    Treatment of pain by subarachnoid administration of sustained-release liposomal anesthetic compositions

    Expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11452691

    Compositions of bupivacaine multivesicular liposomes

    Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11426348

    Compositions of bupivacaine multivesicular liposomes

    Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11357727

    Manufacturing of bupivacaine multivesicular liposomes

    Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11311486

    Manufacturing of bupivacaine multivesicular liposomes

    Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11304904

    Manufacturing of bupivacaine multivesicular liposomes

    Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11278494

    Manufacturing of bupivacaine multivesicular liposomes

    Expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11185506

    Manufacturing of bupivacaine multivesicular liposomes

    Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11179336

    Manufacturing of bupivacaine multivesicular liposomes

    Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11040011

    Zinc meloxicam complex microparticle multivesicular liposome formulations and processes for making the same

    Expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11033495

    Manufacturing of bupivacaine multivesicular liposomes

    Expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10729651

    Sustained release formulation of a non-steroidal anti-inflammatory drug

    Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10709665

    Zinc meloxicam complex microparticle multivesicular liposome formulations and processes for making the same

    Expires Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10675245

    Sustained release formulation of a non-steroidal anti-inflammatory drug

    Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10617642

    Sustained release formulation of a non-steroidal anti-inflammatory drug

    Expires Mon Apr 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10610486

    Sustained release formulation of a non-steroidal anti-inflammatory drug

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10398648

    Method for formulating large diameter synthetic membrane vesicles

    Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10123974

    Sustained release formulation of a non-steroidal anti-inflammatory drug

    Expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10045941

    Method for formulating large diameter synthetic membrane vesicles

    Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10028911

    Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent

    Expires Mon Jul 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9974744

    Sustained release formulation of a non-steroidal anti-inflammatory drug

    Expires Mon May 17 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9808424

    Method for formulating large diameter synthetic membrane vesicles

    Expires Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9770414

    Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent

    Expires Mon Sep 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9757336

    Method for formulating large diameter synthetic membrane vesicles

    Expires Mon Sep 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Pacira Ireland have?

57 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Pacira Ireland patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.